1. Home
  2. CNOB vs AVLN Comparison

CNOB vs AVLN Comparison

Compare CNOB & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOB

ConnectOne Bancorp Inc.

HOLD

Current Price

$32.87

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$35.18

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNOB
AVLN
Founded
1982
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1995
2026

Fundamental Metrics

Financial Performance
Metric
CNOB
AVLN
Price
$32.87
$35.18
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$31.25
N/A
AVG Volume (30 Days)
434.4K
179.6K
Earning Date
04-23-2026
N/A
Dividend Yield
2.48%
N/A
EPS Growth
N/A
N/A
EPS
1.51
N/A
Revenue
N/A
N/A
Revenue This Year
$42.85
N/A
Revenue Next Year
$7.27
N/A
P/E Ratio
$21.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.20
$24.90
52 Week High
$34.14
$35.84

Technical Indicators

Market Signals
Indicator
CNOB
AVLN
Relative Strength Index (RSI) 51.23 67.06
Support Level $31.12 $27.11
Resistance Level $34.04 N/A
Average True Range (ATR) 0.63 1.80
MACD -0.07 0.84
Stochastic Oscillator 67.26 94.94

Price Performance

Historical Comparison
CNOB
AVLN

About CNOB ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: